{
    "clinical_study": {
        "@rank": "52152", 
        "acronym": "RAFA", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Good Risk Patients", 
                "arm_group_type": "Experimental", 
                "description": "Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates .  Busulfan pharmacokinetics will not be used.  All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment.  Cyclosporine will not be used for GVHD prophylaxis.  The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF.  T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).  A maximum of 20 patients will be enrolled on this arm."
            }, 
            {
                "arm_group_label": "Arm B: Intermediate Risk Patients", 
                "arm_group_type": "Experimental", 
                "description": "Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment.  Cyclosporine will not be used for prophylaxis against GVHD.  The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor.  T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).\nThe maximum number of patients enrolled in this arm will be 10."
            }, 
            {
                "arm_group_label": "Arm C: High Risk Patients", 
                "arm_group_type": "Experimental", 
                "description": "Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days).  In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment.  Cyclosporine will not be used for GVHD prophylaxis.  The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF.  T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the use of lower doses of busulfan and the\n      elimination of cyclosporine will further reduce transplant-related side effects for patients\n      with Fanconi Anemia (FA).  Patients will undergo a transplant utilizing mis-matched related\n      or matched unrelated donors following  a preparative regimen of busulfan, fludarabine,\n      anti-thymocyte globulin and cyclophosphamide."
        }, 
        "brief_title": "HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy", 
        "completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Fanconi Anemia", 
            "Severe Marrow Failure", 
            "Myelodysplastic Syndrome (MDS)", 
            "Acute Myelogenous Leukemia (AML)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Fanconi Anemia", 
                "Fanconi Syndrome", 
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The trial proposed is a three arm phase II treatment protocol designed to investigate the\n      safety and efficacy of risk-adjusted  chemotherapy-based cytoreductive regimen plus a CD34+\n      selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the\n      treatment of patients with Fanconi anemia and severe hematologic disease. Candidates for\n      this trial will include patients with Fanconi anemia presenting with severe marrow failure\n      (transfusion dependent) or myelodysplastic syndrome, or acute myelogenous leukemia for whom\n      an allogeneic stem cell transplant is indicated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have a diagnosis of Fanconi anemia\n\n          -  Patients must have one of the following hematologic diagnoses:\n\n               1. Severe Aplastic Anemia (SAA), with bone marrow cellularity of <25% OR Severe\n                  Isolated Single Lineage Cytopenia and at least one of the following features:\n\n                    1. Platelet count <20 x 109/L or platelet transfusion dependence*\n\n                    2. ANC <1000 x 109/L\n\n                    3. Hgb <8 gm/dl or red cell transfusion dependence*\n\n               2. Myelodysplastic Syndrome (MDS) (based on WHO or IPSS Classification\n\n               3. Acute Myelogenous Leukemia (untreated, in remission or with refractory or\n                  relapsed disease)\n\n          -  Donors will be either human leukocyte antigen (HLA) compatible unrelated or\n             HLA-genotypically matched related donors (no fully matched sibling donor).\n\n          -  Patients and donors may be of either gender or any ethnic background.\n\n          -  Patients must have a Karnofsky adult, or Lansky pediatric performance scale status >\n             70%.\n\n          -  Patients must have adequate physical function measured by:\n\n               1. Cardiac:  asymptomatic or if symptomatic then 1) left ventricular ejection\n                  fraction (LVEF) at rest must be > 50% and must improve with exercise or 2)\n                  Shortening Fraction > 29%\n\n               2. Hepatic:  < 5 x upper limit of normal (ULN) SGOT and < 2.0 mg/dl total serum\n                  bilirubin.\n\n               3. Renal:  serum creatinine <1.5 mg/dl or if serum creatinine is outside the normal\n                  range, then CrCl > 50 ml/min/1.73 m2\n\n               4. Pulmonary:  asymptomatic or if symptomatic, DLCO > 50% of predicted\n\n          -  Each patient must be willing to participate as a research subject and must sign an\n             informed consent form.\n\n          -  Female patients and donors must not be pregnant or breastfeeding at the time of\n             signing consent. Women must be willing to undergo a pregnancy test prior to\n             transplant and avoid becoming pregnant while on study.\n\n        Exclusion Criteria:\n\n          -  Active CNS leukemia\n\n          -  Female patients who are pregnant (positive serum or urine HCG) or breast-feeding.\n\n          -  Active uncontrolled viral, bacterial or fungal infection\n\n          -  Patient seropositive for HIV-I/II; HTLV -I/II"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143830", 
            "org_study_id": "2013-7501"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A: Good Risk Patients", 
                    "Arm B: Intermediate Risk Patients", 
                    "Arm C: High Risk Patients"
                ], 
                "description": "A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).\nA higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.\nA lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Myleran", 
                    "Busulfex IV"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A: Good Risk Patients", 
                    "Arm B: Intermediate Risk Patients", 
                    "Arm C: High Risk Patients"
                ], 
                "description": "Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days.  The dose will be adjusted according to patients ideal body weight for obese patients.", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cytoxan"
            }, 
            {
                "arm_group_label": [
                    "Arm A: Good Risk Patients", 
                    "Arm B: Intermediate Risk Patients", 
                    "Arm C: High Risk Patients"
                ], 
                "description": "Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug", 
                "other_name": "Fludara"
            }, 
            {
                "arm_group_label": [
                    "Arm A: Good Risk Patients", 
                    "Arm B: Intermediate Risk Patients", 
                    "Arm C: High Risk Patients"
                ], 
                "description": "Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.", 
                "intervention_name": "rabbit ATG", 
                "intervention_type": "Drug", 
                "other_name": "thymoglobulin"
            }, 
            {
                "arm_group_label": [
                    "Arm A: Good Risk Patients", 
                    "Arm B: Intermediate Risk Patients", 
                    "Arm C: High Risk Patients"
                ], 
                "description": "All patients will also receive G-CSF post-transplant to foster engraftment.", 
                "intervention_name": "G-CSF", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Granulocyte colony-stimulating factor", 
                    "filgrastim", 
                    "neupogen"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A: Good Risk Patients", 
                    "Arm B: Intermediate Risk Patients", 
                    "Arm C: High Risk Patients"
                ], 
                "description": "The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).", 
                "intervention_name": "Peripheral blood stem cell", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Cyclophosphamide", 
                "Fludarabine monophosphate", 
                "Fludarabine", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "marrow aplasia", 
            "cytopenia", 
            "myelodysplasia", 
            "AML", 
            "bone marrow transplant", 
            "cytoreductive regimen", 
            "T-cell reduction"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45229"
                }, 
                "name": "Cincinnati Children's Hospital Medical Center"
            }, 
            "investigator": {
                "last_name": "Parinda Mehta, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine", 
        "other_outcome": [
            {
                "description": "Patients will be observed for acute and/or chronic graft versus host disease (GvHD). Standard clinical criteria for the grading of acute and chronic GvHD will be done according to IBMTR guidelines.", 
                "measure": "Graft Versus Host Disease", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "For patients with MDS or AML, relapse will be analyzed as to type and genetic origin of the MDS/leukemic cells.", 
                "measure": "Leukemic Relapse", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Patients will be followed for 5 years through annual contact with their treatment center in order to track the risk of developing a secondary malignancy.", 
                "measure": "Secondary malignancies", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "overall_contact": {
            "email": "Jamie.Wilhelm@cchmc.org", 
            "last_name": "Jamie Wilhelm", 
            "phone": "(513)803-1102"
        }, 
        "overall_contact_backup": {
            "email": "Michelle.Spaulding@cchmc.org", 
            "last_name": "Michelle Spaulding, RN", 
            "phone": "(513)803-0460"
        }, 
        "overall_official": {
            "affiliation": "CCHMC", 
            "last_name": "Parinda Mehta, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary non-engraftment is diagnosed when the patient fails to achieve an ANC >=500/mm3 at any time in the first 28 days post-transplant. If (1) after achievement of an absolute neutrophil count (ANC) >=500/mm3, the ANC declines to <500/mm3 for more than 3 consecutive days in the absence of relapse, or, (2) there is absence of donor cells in the marrow and/or blood as demonstrated by chimerism assay in the absence of relapse, a diagnosis of secondary graft failure is made. The patient is not evaluable for graft failure or rejection if recurrence of host MDS is detected concurrently.", 
            "measure": "Graft Failure or Rejection", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The occurrence of severe post-transplant regimen-related severe morbidity (grade IV toxicity) and/or mortality will be the second endpoint of this study. In the context of the agents or agent-combination used for cytoreduction used, particular attention will be given to toxicity involving (1) the liver, (2) the lungs, (3) the oral mucosa and gastrointestinal tract, and (4) the central nervous system.", 
            "measure": "Post-transplant severe morbidity and mortality", 
            "safety_issue": "Yes", 
            "time_frame": "2 years post-transplant"
        }, 
        "source": "Children's Hospital Medical Center, Cincinnati", 
        "sponsors": {
            "collaborator": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Children's Hospital Medical Center, Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}